×

Register now for full access to all the content

First Name
Last Name
Company
Title
Country
Thank you for registering!
Error - something went wrong!
   

Commercial Consequences Of Expedited Approval

August 22, 2017

This paper looks at the results from a payer survey, covering all segments of the payer market and representing 226 million lives, aimed at understanding current and future payer practices.

The Network for Excellence in Healthcare Innovation (NEHI) and PAREXEL jointly completed a research program to understand the impact that Expedited regulatory approval (‘acceleration’) is having on the US payer landscape and the commercial potential of products moving, and not moving, through this pathway. 

To achieve this, we completed a payer survey, covering all segments of the payer market and representing 226 million lives, aimed at understanding current and future payer practices. We also reviewed the commercial performance of 26 products, covering 20 accelerated and 6 non-accelerated products across 7 therapy areas. The results are presented in this paper.

Previous Flipbook
Commercialization_Strategy_Willingness_To_Pay_PDF_Casestudy_250215
Commercialization_Strategy_Willingness_To_Pay_PDF_Casestudy_250215

Next Flipbook
Innovation In Real-World Research: Driving Value Through Leading-Edge Technology, Process and Insight
Innovation In Real-World Research: Driving Value Through Leading-Edge Technology, Process and Insight

Read this paper about what the next five years will hold for the industry!